Comparative Pharmacology
Head-to-head clinical analysis: GLYCORT versus QBREXZA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GLYCORT versus QBREXZA.
GLYCORT vs QBREXZA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glucocorticoid receptor agonist; modulates gene expression to produce anti-inflammatory and immunosuppressive effects.
Selective D1 and D5 dopamine receptor antagonist; reduces dopamine-mediated vasodilation in choroidal blood vessels, decreasing choroidal thickness and neovascularization.
Intravenous: 2 mg/kg every 12 hours; Oral: 20 mg twice daily.
1 capsule (40 mg) orally twice daily with or without food.
None Documented
None Documented
3.5 hours (terminal); prolonged in hepatic impairment (up to 8 hours) and severe renal impairment (up to 6 hours)
Terminal elimination half-life is approximately 150 hours (range 120-200 hours), supporting once-daily dosing without significant accumulation.
Renal: 70% as unchanged drug; biliary/fecal: 25% (metabolites); 5% other
Renal: approximately 30% as unchanged drug; fecal: approximately 60% as metabolites and parent compound; biliary excretion contributes to fecal elimination.
Category C
Category C
Anticholinergic
Anticholinergic